PMID- 8136738
OWN - NLM
STAT- MEDLINE
DCOM- 19940425
LR  - 20141120
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 12
IP  - 6
DP  - 1993 Dec
TI  - Interleukin-1 and tumor necrosis factor-alpha as radio- and chemoprotectors of 
      bone marrow.
PG  - 551-63
AB  - Administration of interleukin 1 (IL-1) or tumor necrosis factor-alpha (TNF alpha) 
      protects bone marrow precursor cells (BMPC) from ionizing radiation and 
      antineoplastic drugs. The time of injection is critical: the best protective 
      results being obtained when cytokines are given around 24h prior to the induced 
      injury. Multiple daily cytokine injections that precede irradiation or drug 
      administration are more effective than single ones although single doses are 
      quite effective at increasing survival in mice. Protection is positively 
      correlated with both rapid granulocyte recovery and BMPC survival. Mechanisms 
      involved in BMPC radioprotection include: (1) push to the S/G2 + M or arrest in 
      the G0 phases of the cell cycle by IL-1 or TNF alpha, respectively, and (2) 
      induction of mitochondrial manganous superoxide dismutase synthesis. For BMPC 
      chemoprotection, proposed mechanisms are: (1) increase of aldehyde dehydrogenase 
      synthesis, and (2) modulation of multiple-drug resistant gene expression. 
      Stimulation of glutathione synthesis in BMPC could be operating in both radio- 
      and chemoprotection. These findings point to the relevance of IL-1 or TNF alpha 
      in cancer therapy as a means of reducing BMPC sensitivity to cytoreductive drugs 
      or irradiation (including radioimmunotherapy) as well as in in vitro tumor cell 
      purging with drugs in autologous BMT. Prior administration of these cytokines 
      should be also considered for people in imminent danger of exposure to radiation.
FAU - Dalmau, S R
AU  - Dalmau SR
AD  - Department of Immunology, National Cancer Institute, Rio de Janeiro, Brazil.
FAU - Freitas, C S
AU  - Freitas CS
FAU - Tabak, D G
AU  - Tabak DG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-1)
RN  - 0 (Radiation-Protective Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/antagonists & inhibitors
MH  - Bone Marrow/*drug effects/*radiation effects
MH  - Bone Marrow Cells
MH  - Cell Survival/drug effects/radiation effects
MH  - Colony-Forming Units Assay
MH  - Hematopoietic Stem Cells/cytology/drug effects/radiation effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Interleukin-1/administration & dosage/adverse effects/*pharmacology
MH  - Neoplasms/therapy
MH  - Radiation Injuries/prevention & control
MH  - Radiation-Protective Agents/pharmacology
MH  - Tumor Necrosis Factor-alpha/administration & dosage/adverse effects/*pharmacology
RF  - 165
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
PST - ppublish
SO  - Bone Marrow Transplant. 1993 Dec;12(6):551-63.